###begin article-title 0
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
Association of alleles carried at TNFA -850 and BAT1 -22 with Alzheimer's disease
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 267 271 267 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA</italic>
###xml 354 358 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1</italic>
###xml 377 382 377 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 605 610 605 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
Inflammatory changes are a prominent feature of brains affected by Alzheimer's disease (AD). Activated glial cells release inflammatory cytokines which modulate the neurodegenerative process. These cytokines are encoded by genes representing several interleukins and TNFA, which are associated with AD. The gene coding for HLA-B associated transcript 1 (BAT1) lies adjacent to TNFA in the central major histocompatibility complex (MHC). BAT1, a member of the DEAD-box family of RNA helicases, appears to regulate the production of inflammatory cytokines associated with AD pathology. In the current study TNFA and BAT1 promoter polymorphisms were analysed in AD and control cases and BAT1 mRNA levels were investigated in brain tissue from AD and control cases.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 139 143 139 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1</italic>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
Genotyping was performed for polymorphisms at positions -850 and -308 in the proximal promoter of TNFA and position -22 in the promoter of BAT1. These were investigated singly or in haplotypic association in a cohort of Australian AD patients with AD stratified on the basis of their APOE epsilon4 genotype. Semi-quantitative RT-PCR was also performed for BAT1 from RNA isolated from brain tissue from AD and control cases.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 93 98 87 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 124 129 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 175 180 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 279 284 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 234 239 <span type="species:ncbi:9606">human</span>
APOE epsilon4 was associated with an independent increase in risk for AD in individuals with TNFA -850*2, while carriage of BAT1 -22*2 reduced the risk for AD, independent of APOE epsilon4 genotype. Semi-quantitative mRNA analysis in human brain tissue showed elevated levels of BAT1 mRNA in frontal cortex of AD cases.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
These findings lend support to the application of TNFA and BAT1 polymorphisms in early diagnosis or risk assessment strategies for AD and suggest a potential role for BAT1 in the regulation of inflammatory reactions in AD pathology.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 178 179 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 470 471 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 583 584 556 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 600 605 573 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 611 612 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 615 619 588 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 625 626 598 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 632 637 605 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 643 644 616 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 645 646 618 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 715 720 688 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A </italic>
###xml 733 738 706 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 845 846 818 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
Inflammation is a prominent pathological feature of the Alzheimer's disease (AD) brain, and might be initiated by the extracellular accumulation of amyloid beta (Abeta) peptide [1]. Activated microglia and astrocytes cluster around the Abeta deposits and neurofibrillary tangles of AD brains and can release neurotoxic agents, including complement proteins and pro-inflammatory cytokines, such as interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha (TNFalpha) [2]. Polymorphisms in genes encoding IL-1alpha, IL-1beta, IL-6 and TNFalpha correlate with heightened risk of AD [3]. For example, IL1B -511 [4], IL6 -174 [5] and TNFA -308 [6,7] associate with increased or reduced risk of AD. We showed that the IL1A -889 T/T and IL1B +3954 T/T genotypes mark increased risk for late-onset Alzheimer's disease (LOAD) in an Australian cohort [8].
###end p 11
###begin p 12
###xml 269 274 263 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 285 286 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 287 289 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 357 369 345 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;</italic>
###xml 379 384 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 427 429 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 444 446 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 527 532 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 607 612 589 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 622 624 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 690 692 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 852 857 828 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 926 928 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 929 931 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 986 991 962 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 1004 1009 974 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
When investigating potential genetic risk factors for AD pathology it is important to include established genetic risk factors. The most widely accepted genetic risk factor for late onset-forms of AD (LOAD) is the epsilon4 allele of the gene encoding apolipoprotein E (APOE epsilon4) [9,10]. Two recent studies have explored a potential association between APOE epsilon4 and the TNFA -850T (*2) promoter polymorphism in Irish [11] and Spanish [12] cohorts with conflicting outcomes. While in the Irish cohort possession of the TNFA -850*2 allele significantly increased the risk of dementia associated with APOE epsilon4 [11], no such synergistic effect was detected in the Spanish cohort [12] suggesting that the effect could be population specific or that other genetic or environmental factors may also play a contributing role. The availability of APOE genotype data from previous studies conducted by our research group [13,14] enabled us to investigate the potential link between APOE epsilon4 and TNFA -850*2 in a well characterised Australian cohort.
###end p 12
###begin p 13
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 202 207 202 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 316 321 316 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
TNFA -308*2 (A allele) marks susceptibility to several autoimmune and inflammatory disorders (for a review see [15]) and has higher transcriptional activity than TNFA -308*1 (G allele) [16,17]. However TNFA -308*2 and linked alleles may mark increased risk [6,18] or protection [7,19] against AD, so we investigated TNFA -308 alleles singly or in haplotypic combination with polymorphisms in adjacent candidate genes to elucidate associations of these polymorphisms or haplotypic combinations of the respective alleles with AD pathology in an Australian cohort.
###end p 13
###begin p 14
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 241 246 241 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 637 639 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 655 660 651 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 800 802 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 821 826 817 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 831 836 827 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 953 958 949 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 977 979 973 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 990 995 986 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 1006 1011 1002 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 1142 1144 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1222 1227 1218 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 1261 1266 1251 1256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 1274 1279 1264 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 1290 1295 1280 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 1370 1375 1360 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 1501 1506 1491 1496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
HLA-B associated transcript 1 (BAT1) is implicated in the regulation of several AD-associated cytokines [20,21]. BAT1 is a member of the DEAD-box family of RNA helicases, encoded in the central major histocompatibility complex (MHC) near to TNFA [22]. Members of this family are a group of highly conserved proteins involved in unwinding of RNA secondary structures [23]. DEAD-box proteins have been implicated in a number of different processes involving RNA such as mRNA stabilization [24]. Studies of anti-sense transfectants suggest BAT1 may act as a negative regulator of pro-inflammatory cytokines, namely IL-1, IL-6 and TNFalpha [20]. Furthermore, BAT1 promoter polymorphisms located at positions -22 and -348 can influence transcription through differential binding of transcription factors [21]. The C allele at BAT1 -22 (BAT1 -22*2) is found on a conserved ancestral haplotype associated with an increased risk of immunopathology (HLA-A1, B8, TNFA -308*2, DR3, DQ2) [21]. Neither TNFA -308*2 nor BAT1 -22*2 are unique to this haplotype, but when carried together form a haplospecific marker of a conserved block of the central MHC [25]. Here we present data from an investigation of associations between AD, the APOE epsilon4 genotype and carriage of TNFA -308*2, TNFA -850*2 and BAT1 -22*2 in a well-characterized Australian cohort. In addition, we report on BAT1 mRNA levels examined in frontal cortex (Fc) brain tissue from AD and control cases in order to investigate whether changes in BAT1 expression are associated with AD.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Genotyping
###end title 16
###begin p 17
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 40 45 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 62 67 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 953 958 941 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 988 990 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 991 993 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 994 996 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 997 999 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
###xml 496 504 <span type="species:ncbi:9606">patients</span>
###xml 510 522 <span type="species:ncbi:9606">participants</span>
###xml 543 550 <span type="species:ncbi:9606">Persons</span>
###xml 596 602 <span type="species:ncbi:9606">people</span>
###xml 891 903 <span type="species:ncbi:9606">participants</span>
Alleles carried at BAT1 -22 (G-->C) and TNFA -308 (G-->A) and TNFA -850 (C-->T) promoter polymorphisms was determined in 631 individuals from a population of Northern European descent (97% Caucasian). There were 359 control donors (45.7% females) with age at venipuncture of 76.7 +/- 13.1 years (mean +/- SD) and 272 AD cases (59.2% females, age: 77.1 +/- 10.5). 391 cases were patients recruited from a memory clinic in Perth, Western Australia (226 AD cases and 165 controls). The remainder of patients were participants in the Sydney Older Persons Study; a random sample of community-dwelling people aged 75 and over at recruitment. Of these, 46 were classified as having AD at assessment, while 194 had no cognitive impairment and were used as controls for this analysis. All studies were conducted with approval from the institutional ethics committees and with informed consent of the participants. Methods of recruitment, diagnostic criteria and APOE genotyping were as described [13,14,26,27].
###end p 17
###begin p 18
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 189 193 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 264 265 263 264 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 735 738 698 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alw</italic>
###xml 1030 1031 993 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Genomic DNA was extracted from peripheral lymphocytes using a standard protocol [28]. BAT1 -22 alleles were determined by PCR amplification in a total volume of 20 muL, containing 1.0 U of Taq polymerase (Fisher Biotec, Australia), 0.2 mM each dNTP and 3.0 mM MgCl2, on a Mastercycler Gradient thermal cycler (Eppendorf, Germany) as follows: 1 cycle of 95degreesC for 5 minutes, 44 cycles of 95degreesC for 30 seconds, 56degreesC for 35 seconds and 72degreesC for 40 seconds, followed by 1 cycle of 72degreesC for 10 minutes. The oligonucleotide primers, (P1) 5'-CAACCGGAAGTGAGTGCA -3' and (P2) 5'-CAGACCATCGCCTGTGAA-3', were purchased from Genset Pacific Pty. Ltd (Lismore, Australia). Amplicons were digested at 37degreesC using 5 U Alw44I (restriction sequence GTGCAC), separated on 8% non-denaturing polyacrylamide gel at 110 V for 1.5 hours and stained with ethidium bromide to reveal DNA fragments with migration patterns specific for each allele (Allele 1 (G) = 170 base pairs (bp); Allele 2 (C) = 152 bp and 18 bp; Figure 1).
###end p 18
###begin p 19
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>BAT1 </italic>-22 G/C promoter polymorphism genotyping</bold>
BAT1 -22 G/C promoter polymorphism genotyping. A representation of a typical -22 C/G genotyping gel produced after digested PCR product was run on an 8% non-denaturing PAGE gel. M = Marker (100 base pair marker - arrows represent 400, 300 and 200 bp fragments). Black arrowheads correspond to allele fragments: -22 C = 152 bp & 18 bp, and -22 G = 170 bp. Lane 1 = -22 CC genotype. Lanes 2,4,5,7,8,9,10 and 11 = -22 CG genotype. Lanes 3 and 6 = -22 GG genotype.
###end p 19
###begin p 20
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 102 108 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TAQti </italic>
###xml 165 167 164 166 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 426 427 395 396 <underline xmlns:xlink="http://www.w3.org/1999/xlink">C</underline>
###xml 607 612 570 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NcoI </italic>
TNFA -308 alleles were determined via PCR amplification in a total volume of 20 muL, containing 0.6 U TAQti (Fisher Biotec, Australia), 0.2 mM each dNTP, 1.5 mM MgCl2 and 0.5 mg/ml BSA amplified as follows: 1 cycle of 94degreesC for 2 minutes, 35 cycles of 94degreesC for 30 seconds, 63degreesC for 30 seconds and 72degreesC for 30 seconds, followed by 1 cycle of 72degreesC for 5 minutes. Primers, (P1) 5'-AGGCAATAGGTTTTGAGGGCCAT-3' (underline denotes mismatch) and (P2) 5'-TCCTCCCTGCTCCGATTCCG-3', were purchased from Proligo Pty. Ltd (Lismore, Australia). Amplicons were digested at 37degreesC using 3 U NcoI (restriction sequence C▲CATGG), separated on 5% high resolution agarose gels at 280 V (12 minutes) and stained with ethidium bromide to reveal fragments with migration patterns specific for each allele (Allele 1 (G) = 88 bp and 19 bp; Allele 2 (A) = 107 bp).
###end p 20
###begin p 21
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 105 111 104 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TAQti </italic>
###xml 179 181 178 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 448 450 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 481 482 450 451 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 663 670 626 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HincII </italic>
###xml 936 938 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
TNFA -850 alleles were determined via PCR amplification in a total volume of 20 muL, containing 0.6 U of TAQti polymerase (Fisher Biotec, Australia), 0.2 mM each dNTP, 1.5 mM MgCl2 and 0.5 mg/ml BSA as follows: 1 cycle of 94degreesC for 3 minutes, 35 cycles of 94degreesC for 45 seconds, 60degreesC for 30 seconds and 72degreesC for 45 seconds, followed by 1 cycle of 72degreesC for 5 minutes. Primers were modified from those initially published [27]. (P1) 5'-TCGAGTATCGGGGACCCCCCGTT-3' (underline denotes mismatch) and (P2) 5'-CCAGTGTGTGGCCATATCTTCTT-3' were purchased from Proligo Pty. Ltd (Lismore, Australia). Amplicons were digested at 37degreesC using 3 U HincII (restriction sequence GTT▲AAC), separated on a 5% high resolution agarose gels at 280 V (12 minutes) and stained with ethidium bromide to reveal DNA fragments with migration patterns specific for each allele (Allele 1 (C) = 105 bp and 23 bp; Allele 2 (T) = 128 bp) [29].
###end p 21
###begin title 22
Brain tissue samples
###end title 22
###begin p 23
###xml 301 306 301 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
Total RNA and protein was isolated from brain tissue (frontal cortex) samples from subjects with histopathologically confirmed definite AD and control cases without any AD pathology. Autopsy was performed within 48 hours after death. Subjects with PS1 mutations and a number of familial AD cases with APOE epsilon4 genotypes were from local pedigrees and from the brain tissue bank of Drexel University College of Medicine (Philadelphia, PA, USA). Control brain tissue was obtained locally (Western Australia) and tissues were also received from the New South Wales (NSW) Tissue Resource Centre (Sydney, NSW, Australia), which is supported by The University of Sydney, Neuroscience Institute of Schizophrenia and Allied Disorders, National Institute of Alcohol Abuse and Alcoholism and NSW Department of Health.
###end p 23
###begin title 24
RNA extraction and semi-quantitative RT-PCR
###end title 24
###begin p 25
###xml 35 39 35 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Total RNA was isolated using Trizol(R) (Gibco BRL, Grand Island, New York, USA) according to manufacturer's instructions. RNA was extracted from 100 mg of frontal cortex brain tissue from 12 cases with familial AD either with PS1 mutations or linked to inheritance of the APOE-epsilon4 allele (mean age at time of death: 63 years, range: 50 - 77) and from 16 control cases without AD pathology (mean age at time of death: 50.25 years, range: 18 - 74 years). RNA concentrations were determined spectrophotometrically and 1 mug aliquots were reverse transcribed using the Omniscripttrade mark Reverse Transcriptase Kit (QIAGEN; Victoria, Australia).
###end p 25
###begin p 26
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 54 65 54 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-ACTIN </italic>
###xml 350 355 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 387 389 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 575 579 560 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 828 832 795 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1</italic>
###xml 849 859 810 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-ACTIN</italic>
###xml 880 885 832 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
Primers required to assess the expression of BAT1 and beta-ACTIN mRNA were purchased from Genset Pacific Pty. Ltd (Lismore, Australia): BAT1(F): 5'-AGAGGCTCTCTCGGTATCA-3', BAT1(R): 5'-GCTGATGTTGACCTCGAAA-3', BACTIN(F): 5'-TGGAATCCTGTGGCATCCATGAAAC-3', BACTIN(R): 5'-TAAAACGCAGCTCAGTAACAGTCCG-3'. Primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were as previously described [30]. 5 muL cDNA was amplified in a 20 muL reaction on a LightCyclertrade mark (Roche, USA). Each 20 muL PCR reaction contained 1.25 mM dNTP, 20 pmol each primer, 0.25 mg/mL BSA, 1.5 units Taq Platinum polymerase and 0.5 x SYBR Green (Invitrogen, USA). Amplifications of cDNA were performed as follows: Denaturation at 95degreesC for 5 minutes, followed by amplification with 44 cycles at 94degreesC for 30 seconds, annealing (62degreesC for BAT1, 64degreesC for beta-ACTIN, and 65degreesC for GAPDH) for 15 seconds and 72degreesC for 40 seconds. Amplicons were separated on 1% TBE agarose gels and visualised by ethidium bromide staining. The quantification of cDNA was achieved with SYBR Green I dye (Sigma, USA).
###end p 26
###begin p 27
###xml 394 399 384 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 548 552 538 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1</italic>
###xml 578 589 568 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-ACTIN </italic>
###xml 593 599 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 630 635 617 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
Standard curves were generated using 10-fold dilutions of a previously purified bulk cDNA PCR product (stored at a concentration of 1 ng/muL) and analysed using a 'fit points' method with the LightCyclertrade mark run software, version 4.0. Melting curve analyses were used to confirm the generation of a single product. This was further confirmed by agarose gel electrophoresis. The amplified BAT1 PCR products were sequenced using big-dye terminator chemistry on an ABI automated DNA sequencer (ABI, USA) to confirm the specific amplification of BAT1. The house keeping genes beta-ACTIN and GAPDH were used for normalization of BAT1 mRNA expression. Statistical significance analysis was performed using the Mann-Whitney U test.
###end p 27
###begin p 28
###xml 250 252 248 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 883 885 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
The Statistical Package for Social Sciences (SPSS version 11.5; SPSS Inc., Chicago, Illinois, USA) was used to establish genotype and allele frequencies and to check for Hardy-Weinberg equilibrium (HWE). Initial data comparison involved Pearson's chi2 and odds ratio (OR) analysis of two by two contingency tables to compare the relative genotype frequencies in AD and control groups. SPSS was further employed to perform Cochran Armitage testing for trends where assumptions of HWE were not met. The same programme was also used to perform direct logistic regression analysis, where all variables were entered into the equation simultaneously to determine the overall contribution of each genotype on AD in this cohort, whilst controlling for established AD risk factors (age and gender). Estimation of linkage disequilibrium and analysis of haplotypes was performed using Thesias [31].
###end p 28
###begin p 29
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 129 134 129 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
GenBank codes for genes investigated in this study include APOE (MIM: 107741, GeneID: 348), TNFA (MIM: 191160, GeneID: 7124) and BAT1 (MIM: 142560, GeneID: 7919).
###end p 29
###begin title 30
Results
###end title 30
###begin p 31
###xml 25 26 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 64 69 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 164 169 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 196 197 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 259 264 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 362 363 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 379 381 375 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 404 409 400 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 665 666 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 769 771 763 765 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 872 877 866 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 923 928 917 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 954 959 948 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 1010 1011 1004 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Pearson's chi-square (chi2) and Odds ratio (OR) analysis of the BAT1 -22 1/1 and 1/2 genotypes revealed a significant association between a complete absence of the BAT1 -22*2 allele and AD (Table 1). However, this apparent level of protection afforded by the BAT1 -22*2 allele revealed no gene dosage effect and was limited to homozygosity of this allele (Table 1). Pearson's chi2 and OR analysis of the TNFA -308 single nucleotide polymorphism (SNP) revealed a weak yet mildly significant trend whereby possession of the -308*2 allele conferred protection from the development of AD. However, this was only significant when allele frequencies were analysed (Table 1). No significant protective effect was observed when genotype frequencies were analysed. Pearson's chi2 and OR analysis of genotype and allele frequencies from data generated through the genotyping of the TNFA -850 SNP revealed a strong association of the TNFA -850*2/2 genotype and the TNFA -850*2 allele with an increased risk for AD (Table 1).
###end p 31
###begin p 32
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
Analysis of Genotype and Allele frequencies of the BAT1 -22, TNFA -308 and TNFA -850 polymorphisms
###end p 32
###begin p 33
Ctrl = Control cases without AD pathology
###end p 33
###begin p 34
AD = Alzheimer's disease cases
###end p 34
###begin p 35
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 2 7 2 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 37 39 37 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 58 60 56 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
a BAT1 -22*2/2 versus non-2/2 in AD, P < .005 (Pearson chi2 = 8.49) OR = 0.43 (95% CI = 0.24 - 0.77).
###end p 35
###begin p 36
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 2 7 2 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 28 30 28 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 49 51 47 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
b TNFA -308*2 allele in AD, P = .048 (Pearson chi2 = 3.91) OR = 0.75 (95% CI = 0.57 - 1.00).
###end p 36
###begin p 37
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 2 7 2 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 41 43 41 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 62 64 60 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
c TNFA -850*(2/2, 1/2) versus 1/1 in AD, P < .001 (Pearson chi2 = 13.06) OR = 1.94 (95% CI = 1.35 - 2.78.0).
###end p 37
###begin p 38
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d </sup>
###xml 2 7 2 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 28 30 28 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 49 51 47 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
d TNFA -850*2 allele in AD, P < .001 (Pearson chi2 = 16.57) OR = 1.90 (95% CI = 1.39 - 2.59).
###end p 38
###begin p 39
###xml 27 29 25 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 304 309 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 313 318 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 346 347 342 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 349 351 345 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 509 514 505 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 523 528 519 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 537 539 531 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 545 547 539 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 645 647 637 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 733 735 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
By convention Pearson's chi2 and OR analysis are commonly used to evaluate data generated from large genotyping studies and explore frequency distributions. However, in order for such analysis to produce meaningful outcomes strict conditions of HWE must be met. In the current study the distributions of APOE and BAT1 -22 alleles were in HWE (chi2, P = .54 and p = .97, respectively) within the control populations. However significant deviation from HWE within the control group populations was observed for TNFA -850 and TNFA -308 (chi2 test, P < .005). Therefore, subsequent analyses employed Armitage's trend test (rather than Pearsons's chi2 analysis), to correct for potential type I errors associated with departure from HWE [32].
###end p 39
###begin p 40
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 98 100 90 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 110 112 102 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 123 128 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 250 255 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 268 269 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 317 322 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 395 396 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 464 465 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 515 520 507 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 614 616 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
Armitage's testing for trends revealed a significant association between APOE epsilon4 and AD (chi2 = 108.91, P < 0.0001). TNFA -850*2 was also significantly associated with increased risk for AD while a significant protective trend was observed for BAT1 -22*2 (Table 2). The protective effect initially observed for TNFA -308*2 in the genotype and allele frequency distribution analysis (Table 1) did not reach significance using Armitage's test for trend (Table 2). This may reflect a haplotypic association with BAT1 -22*2 since the alleles are in linkage disequilibrium (LD) in the West Australian population [25].
###end p 40
###begin p 41
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
Armitage test for trend for BAT1 and TNFA genotypes
###end p 41
###begin p 42
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Logistic regression analysis including age and gender associated BAT1 -22*2/2 with protection against AD, while TNFA -850*1/2 and TNFA -850*2/2 conferred risk (Table 3). These findings support Armitage's test for trend results and suggest a possible gene dosage effect for the presence of the TNFA -850*2 allele.
###end p 42
###begin p 43
Direct logistic regression analysis
###end p 43
###begin p 44
Direct logistic regression model with Odds ratios representing risk assessment for AD.
###end p 44
###begin p 45
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
a Homozygosity of BAT1 -22*2 allele (with absence of allele as reference).
###end p 45
###begin p 46
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
b Heterozygosity of TNFA -850*2 allele (with absence of allele as reference).
###end p 46
###begin p 47
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
c Homozygosity of TNFA -850*2 allele (with absence of allele as reference).
###end p 47
###begin p 48
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 92 97 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 101 106 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 164 169 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 183 188 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 197 202 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 214 219 202 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 273 278 261 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 426 433 414 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 466 471 454 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 534 539 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 587 592 569 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 618 623 600 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
Additional logistic regressions analysis of interaction terms between APOE epsilon4 and the TNFA and BAT1 SNPs showed no interactions between the effects marked by APOE epsilon4, and BAT1 -22*2/2, TNFA -850*1/2 or TNFA -850*2/2. Furthermore, a stratified analysis based on APOE genotype using the Mantel-Haenszel technique showed no significant differences in Odds ratios when estimating effects on AD risk of individual SNPs versus a combination of these SNPs with APOE epsilon4. This suggests that the observed protective effect of BAT1 - 22*2/2 and the increased risk associated with TNFA -850*2 are independent of APOE epsilon4 genotype.
###end p 48
###begin p 49
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 236 241 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 246 251 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 466 471 466 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 490 492 490 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 559 564 559 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 638 643 638 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 666 671 666 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 724 729 724 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 766 771 766 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 823 828 823 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 890 895 890 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 940 945 940 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
BAT1 and TNFA are located in close proximity within the MHC [21,22] and their alleles are in marked LD [25]. Therefore, the computer programme Thesias [31] was used to generate LD matrices for analysis of LD and for haplotype analysis. BAT1 -22, TNFA -308 and TNFA -850 were all in LD, so haplotype frequencies were estimated under LD for all three markers and combinations of two markers. The only significant result was obtained for BAT1 -22*1 in combination with TNFA -850*2 (OR = 1.54, P < 0.05). However, the individual Odds ratios for TNFA -850*1/2 and TNFA -850*2/2 were higher than for the above haplotype (i.e. individual OR for TNFA -850*1/2 = 1.8 and for TNFA -850*2/2 = 2.7). This indicates that the presence of BAT1 -22*1 in haplotypic association with TNFA -850*2 cannot explain the risk effects conferred by TNFA -850*2. Therefore, both the protective effect associated with BAT1 -22*2 and the increased risk associated with TNFA -850*2 are more likely due to the individual SNPs themselves or a potential haplotypic association with other genes.
###end p 49
###begin p 50
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DDXL </italic>
###xml 211 216 211 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 311 322 311 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-ACTIN </italic>
###xml 351 357 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 404 409 401 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 460 462 457 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 473 475 470 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
In order to test whether transcription of BAT1 and the homologous gene DDXL was altered in AD, mRNA levels of both BAT1 and DDXL were examined in brain frontal cortex tissue of AD and control cases. Analysis of BAT1 mRNA levels (Figure 2) revealed significantly elevated mRNA levels for BAT1 normalized against beta-ACTIN (a) while normalization with GAPDH (b) showed marginal significance for increased BAT1 mRNA levels in the AD brains (Mann-Whitney U test: P = .037 and P = .057 respectively).
###end p 50
###begin p 51
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DDXL </italic>
###xml 0 106 0 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Semi-quantitative RT-PCR of <italic>BAT1 </italic>and <italic>DDXL </italic>mRNA in frontal cortex of AD (n = 12) and control cases (n = 16)</bold>
###xml 182 187 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 218 229 218 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-ACTIN </italic>
###xml 252 254 249 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 267 272 264 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 303 309 300 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 333 335 330 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Semi-quantitative RT-PCR of BAT1 and DDXL mRNA in frontal cortex of AD (n = 12) and control cases (n = 16). Data is represented as Box-plots showing median values and quartiles. (A) BAT1 mRNA levels normalized against beta-ACTIN (Mann-Whitney U test: *P = .037), (B) BAT1 mRNA levels normalized against GAPDH (Mann-Whitney U test: **P = .057).
###end p 51
###begin title 52
Discussion
###end title 52
###begin p 53
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 272 277 272 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 296 297 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 693 698 693 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
AD is a multifactorial disorder with a number of alterations in the immune profile occurring during disease progression in both the brain [33] and the periphery [34,35]. Recently studies have reported links between risk for AD and polymorphisms in the promoter regions of TNFA at positions -308 [6,18] and -850 [11]. The current study utilized a well characterised sample to investigate these potential associations in an Australian cohort. In addition, BAT1 has been implicated in modulation of inflammatory cytokines [20]. Therefore, the current study investigated alleles of the BAT1 -22 promoter polymorphism as a potential risk factor for AD, singly or in haplotypic association with the TNFA promoter polymorphisms.
###end p 53
###begin p 54
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 360 365 360 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 628 633 628 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
Analysis of individual SNPs revealed no significant association between AD and TNFA -308*2. This contrasts with reports in the literature that associate the TNFA -308*2 allele with either increased risk for AD [6,18] or protection against this disorder [7,19]. While data from the current study appears to be more supportive of a potential protective role for TNFA -308*2 against AD (Table 1), no conclusions can be drawn solely based on genotype and allele frequency analysis due to control group deviations from HWE that might affect the rate of type I error. However, it is possible that the inconclusive result obtained for TNFA -308*2 may be due to haplotypic associations of this polymorphism with other MHC markers such as the BAT1-22*2 allele.
###end p 54
###begin p 55
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 104 109 104 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 377 382 377 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 475 480 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 521 523 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 654 659 648 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 670 675 664 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 685 687 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 961 966 949 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 1042 1044 1030 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
In contrast to the ambiguous result obtained for TNFA -308*2, analysis of individual SNPs revealed that TNFA -850*2 was clearly significantly associated with increased risk for AD. The literature shows association of the TNFA -850*2 with vascular dementia [11] and individuals at high risk for dementia, such as those with Down's Syndrome [36]. However, a clear association of TNFA -850*2 with AD has only previously been reported as a synergistic effect in combination with APOE epsilon4 in a Northern Irish population [11], while a similar study in a population from Northern Spain failed to produce evidence in support of a synergistic effect between TNFA -850*2 and APOE epsilon4 [12]. The authors suggested that this discrepancy might reflect true genetic differences between the populations and pointed out that differences in allele frequency distributions between the two different European populations might indicate linkage disequilibrium between the TNFA -850 and another marker that might represent the true disease causing gene [12].
###end p 55
###begin p 56
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 265 270 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 365 370 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 483 488 477 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 579 591 573 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;</italic>
The current study presents data in support of the notion that TNFA -850*2 contributes to the risk of AD independently of the APOE epsilon4 allele. Furthermore, logistic regression analysis revealed a possible gene dosage effect with increase in copy numbers of the TNFA -850*2 allele leading to higher Odds ratios. It is, however, possible that a gene linkage with TNFA -850*2 would show a parallel OR pattern, and might account for the apparent gene dosage effect attributed to the TNFA -850*2 allele. Since all three markers investigated exerted their effects independently of APOE epsilon4 but were found to be in LD with one another, haplotype frequencies, taking into account LD between markers, were estimated for all three MHC markers and also for combinations of two markers in order to investigate whether an AD risk or protection associated haplotype could be responsible for the effects observed.
###end p 56
###begin p 57
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 257 262 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 285 290 285 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 374 379 374 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 681 686 681 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 814 825 <span type="species:ncbi:9606">participant</span>
Only one haplotype (BAT1 -22*1 in combination with TNFA -850*2) appeared to be significantly associated with risk for AD, but the observed Odds ratio was lower for this haplotype (OR = 1.54) than the OR for the single polymorphisms associated with AD risk (TNFA -850*1/2, OR = 1.8 and TNFA -850*2/2, OR = 2.7). This indicates that, although in LD with the other two markers TNFA -850*2 did not exert its risk for AD through a haplotypic association with these polymorphisms. While it cannot be entirely ruled out that linkage disequilibrium with other as yet not identified markers may be responsible for the effect observed in this investigation, the current study identifies the TNFA -850*2 allele as a candidate marker that may confer risk for AD in the Australian population. Further investigation with larger participant numbers and in other populations is clearly warranted.
###end p 57
###begin p 58
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 224 228 220 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1</italic>
###xml 420 425 416 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 465 469 461 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1</italic>
###xml 508 513 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 602 607 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 655 660 645 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 723 727 713 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1</italic>
While the polymorphisms in the promoter regions of TNFA are likely to directly affect transcription of the TNFA gene, ultimate levels of TNFalpha protein in tissues can also be influenced by other regulating factors such as BAT1. In the current study BAT1-22*2/2 was significantly associated with protection against the development of AD. Similar to the association between increased risk for AD and the presence of the TNFA -850*2 allele, the protective effect of BAT1-22*2/2 was found to be independent of APOE epsilon4 status. Furthermore, none of the estimated haplotypic associations with the two TNFA markers that are in linkage disequilibrium with BAT1 have provided evidence to suggest that the effect observed for BAT1-22*2/2 is due to a haplotypic association with these markers. While the possibility remains that the protective BAT1 effect might be due to LD with another gene as yet not investigated, it is also possible that BAT1 might assert an independent effect on AD risk.
###end p 58
###begin p 59
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 345 349 345 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA</italic>
###xml 471 476 471 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 492 497 492 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 820 825 820 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
A potential independent role for BAT1 in AD pathology is supported by the notion that the BAT1 -22 polymorphism may not only have the potential to affect transcription of BAT1 but, through the role BAT1 plays in mRNA stabilization, this protein may also affect translation of a number of inflammatory cytokines linked to AD pathology, including TNFA. It has previously been reported that BAT1 plays a potential role in the regulation of inflammatory cytokines, including TNFA [20,21] and the BAT1 -22 allele has been associated with certain autoimmune disease susceptible ancestral haplotypes such as the 8.1 MHC AH amongst others [21]. Since BAT1 appears to regulate a number of inflammatory cytokines for which alterations are observed in AD pathology the current study is the first to provide evidence to show that a BAT1 promoter polymorphism is significantly associated with AD pathology.
###end p 59
###begin p 60
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 769 774 769 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 884 889 884 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 904 906 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 996 1004 996 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xenopus </italic>
###xml 1045 1056 1045 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 1137 1139 1137 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1140 1142 1140 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1318 1323 1318 1323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 1515 1519 1515 1519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT </italic>
###xml 1532 1539 1532 1539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 1762 1767 1762 1767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 1855 1859 1855 1859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1</italic>
###xml 1957 1962 1957 1962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 618 623 <span type="species:ncbi:4932">yeast</span>
###xml 996 1003 <span type="species:ncbi:8355">Xenopus</span>
###xml 1045 1055 <span type="species:ncbi:7227">Drosophila</span>
It is of interest to note that for the TNFA -850 polymorphism the less frequent allele conferred risk for AD while the opposite was found for the less frequent allele (C) of the BAT1 -22 polymorphism which was associated with a decreased risk for AD. This finding that the BAT1 -22*2 (C) allele is associated with protection against AD is in contrast to the findings for autoimmune disorders where the less common number 2 allele is implicated with ancestral haplotypes that confer increased risk [20,21]. In order to explain this phenomenon it is important to gain a better understanding of the function of BAT1. The yeast homolog of BAT1, Sub2p, has been shown to be required for mRNA export through nuclear pores [37,38]. Previous findings have shown that the -22 C BAT1 allele, associated with the autoimmune disease susceptible 8.1 MHC ancestral haplotype, may result in reduced BAT1 transcription [21]. However, it has also been demonstrated that both injection of excess UAP56 (BAT1) into Xenopus oocytes as well as depletion of HEL, the Drosophila homologue of UAP56, by RNAi resulted in defects in mRNA export from the nucleus [39,40]. This indicates that both excess levels of BAT1 and a lack of this protein can lead to abnormalities in mRNA export and splicing. Hence, the presence of different alleles of BAT1 -22 may potentially lead to a range of different aberrations in mRNA processing resulting in a variety of different phenotypic manifestations of pathology. It is, therefore, possible that the BAT -22*2 allele per se may be protective against AD but still also be part of an array of SNPs that may confer risk for certain autoimmune disorders. The complexity of potential phenotypical effects as well as possible haplotypic associations of BAT1 -22 with other genes indicate that further studies are warranted to explore whether the BAT1-22*1 allele may confer an independent risk for AD other than just in haplotypic combination with TNFA -850*2 as observed in the current study.
###end p 60
###begin p 61
Therefore, while the possibility of LD with other genes cannot be ruled out the current study provides evidence in support for a potential role for BAT1 in AD pathology. BAT1 -22 and TNFA -850 in combination with other biochemical and cognitive markers might serve as genetic markers for diagnostic purposes or AD risk assessment strategies. Moreover, in light of current international drug development research in the AD field, establishment of genetic profiles may help to identify individuals more likely to experience benefits from certain treatments or may prevent individuals genetically unfavourably predisposed from receiving costly, yet ineffective treatment. Since the SNPs investigated could also lead to functional differences it is of great importance to investigate phenotypical characteristics conferred by these polymorphisms.
###end p 61
###begin p 62
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 256 261 256 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 291 296 291 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 417 422 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 426 431 426 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DDXL </italic>
Considering that BAT1 has a potential regulatory role for inflammatory cytokines [20,21] analysis of BAT1 mRNA and protein levels in AD brain tissue may reveal a functional role for the BAT1 protein in AD pathology. To investigate whether transcription of BAT1 was affected in AD, levels of BAT1 mRNA were determined in brain tissue from confirmed AD and control cases. This revealed significantly elevated levels of BAT1 and DDXL mRNA in Fc of AD cases and suggests a potential functional role for BAT1 in AD pathogenesis. It is not implausible to suggest that levels of BAT1 may rise as a response mechanism to counteract the inflammatory reactions that occur in regions of AD pathology. However, a repetition of this study with a larger sample size to enable parametric analysis of results may help to confirm the significance of these findings.
###end p 62
###begin p 63
###xml 145 150 145 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 422 427 422 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 532 534 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 608 609 600 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 705 710 697 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 821 826 813 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
These data are of particular interest in light of recent findings that oligonucleotides spanning the promoter polymorphism -22 to -348 region of BAT1 autoimmune disease resistant 7.1 AH bind DNA/protein complexes as shown by electrophoretic mobility shift assays [41]. At position -22 these complexes appear to include the octamer binding protein family member, transcription factor Oct1 [39]. Oct1 has been shown to bind TNFA at position -857T and can interact with the pro-inflammatory NF-kappaB transcription factor p65 subunit [42]. As TNFalpha has been implicated in inflammation observed in AD brains [2] the above studies together with the current findings suggest an important association between BAT1 expression and regulation of inflammatory cytokines in the AD brain. The exact mechanisms of this link between BAT1 -22 promoter polymorphism and inflammatory reactions in the AD brain remain to be explored in future studies.
###end p 63
###begin p 64
###xml 182 187 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
To establish the role of BAT1 in AD pathology it is imperative to examine levels of BAT1 in AD affected tissues in a larger number of cases. Apart from its presence in brain tissue, BAT1 mRNA transcripts have been detected in pancreas, kidney, skeletal muscle, liver, lung and heart [43]. The presence of BAT1 in hematopoietic cells [20] makes this protein a potential biomarker in early diagnosis or monitoring of progression of disorders with inflammatory responses, such as AD.
###end p 64
###begin title 65
Conclusion
###end title 65
###begin p 66
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 75 80 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 122 127 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 163 168 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
###xml 726 731 714 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT1 </italic>
The current study has revealed an APOE epsilon4 independent association of TNFA -850*2 with increased risk for AD, and an APOE epsilon4 independent association of BAT1 -22*2/2 with decreased risk for AD. These findings were not enhanced by haplotype analysis of polymorphisms in linkage disequilibrium suggesting that the observed effects may have resulted from the single SNPs. Hence, these SNPs may represent valuable markers in risk assessment, prognosis and therapeutic approaches for AD. In addition, the current study has provided evidence for a novel role for BAT1 in AD pathogenesis. BAT1 may play a role in regulating the inflammatory response in AD through influencing mRNA export and translation. Investigations of BAT1 promoter polymorphisms and mRNA and protein levels in other populations are clearly warranted to confirm this initial finding. Inflammatory processes form important underlying mechanisms in AD pathology. Elucidating the role of the currently investigated SNPs in AD pathology may contribute towards an understanding of the regulatory mechanisms of these events, and may provide new targets for drug development to combat AD.
###end p 66
###begin title 67
Competing interests
###end title 67
###begin p 68
The authors declare that they have no competing interests.
###end p 68
###begin title 69
Authors' contributions
###end title 69
###begin p 70
AG has isolated RNA from AD and control brain tissue and has been drafting and writing the manuscript, has performed data analysis for the mRNA work, and has been involved in interpretation of data and revising the manuscript critically for important intellectual content. KD has performed the semi-quantitative RT-PCR and data analysis and has made substantial contributions towards drafting the manuscript. SML has made substantial contributions towards genotyping, data analysis and interpretation and drafting of the manuscript. RH, KB and KT contributed towards the genotyping process. GM and AP have been involved in the sample acquisition and/or the DNA extraction process. GV and SEG have made substantial intellectual contributions towards the manuscript. GAB, WSB, HB and OP were involved in sample acquisition and processing. PP has made substantial contributions to the concept and design of the study and the manuscript as expert adviser, and has contributed towards data interpretation. JM contributed towards analysing brain tissue from a substantial proportion of the cases for histopathological diagnosis. JH has been critically involved in statistical analyses and interpretation of data, including genotype and haplotype analyses. PM has provided substantial expert advice with regard to analysis and interpretation of data and manuscript drafting. RNM has made the most substantial contributions towards the conception and design of the study and has given final approval of the version to be published. All of the authors have read and approved the final manuscript.
###end p 70
###begin title 71
Acknowledgements
###end title 71
###begin p 72
This project was supported by the McCusker Foundation for Alzheimer's Disease Research, Edith Cowan University and Hollywood Private Hospital, Department of Veteran Affairs and the NHMRC. The authors would also like to acknowledge the excellent help in form of statistical analysis contributed by Dr Karen Josebury. Furthermore, the authors would like to acknowledge the Sir Zelman Cowen Universities' Fund which provided funding for collection of blood samples. We thank Dr Noel Tan for dissection and histopathological examination of brains. We also extend our thanks to Dr Clive Cooke (Queen Elizabeth Medical Centre, Perth, WA, Australia) for dissection and macroscopic examination of brains. Furthermore, we would like to thank Professor Glenda Halliday (Prince of Wales Medical Research Institute, Randwick, NSW, Australia) for valuable discussion with regard to the brain samples used.
###end p 72
###begin article-title 73
The importance of inflammatory mechanisms in Alzheimer disease
###end article-title 73
###begin article-title 74
Microglia as mediators of inflammatory and degenerative diseases
###end article-title 74
###begin article-title 75
Polymorphisms in inflammatory genes and the risk of Alzheimer disease
###end article-title 75
###begin article-title 76
Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism
###end article-title 76
###begin article-title 77
Interleukin-6-174 G/C promoter gene polymorphism C allele reduces Alzheimer's disease risk
###end article-title 77
###begin article-title 78
Association between the TNFalpha-308 A/G polymorphism and the onset-age of Alzheimer disease
###end article-title 78
###begin article-title 79
Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease
###end article-title 79
###begin article-title 80
Association of interleukin-1 polymorphisms with Alzheimer's disease in Australia
###end article-title 80
###begin article-title 81
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
###end article-title 81
###begin article-title 82
Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease
###end article-title 82
###begin article-title 83
Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study
###end article-title 83
###begin article-title 84
No synergistic effect between -850 tumor necrosis factor-alpha promoter polymorphism and apolipoprotein E epsilon 4 allele in Alzheimer's disease
###end article-title 84
###begin article-title 85
ApoE genotypes in Australia: roles in early and late onset Alzheimer's disease and Down's syndrome
###end article-title 85
###begin article-title 86
Evidence that the butyrylcholinesterase K variant can protect against late-onset Alzheimer's Disease
###end article-title 86
###begin article-title 87
Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases
###end article-title 87
###begin article-title 88
###xml 35 40 <span type="species:ncbi:9606">human</span>
An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles
###end article-title 88
###begin article-title 89
###xml 33 38 <span type="species:ncbi:9606">human</span>
Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation
###end article-title 89
###begin article-title 90
Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative
###end article-title 90
###begin article-title 91
###xml 115 123 <span type="species:ncbi:9606">patients</span>
Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls
###end article-title 91
###begin article-title 92
The central MHC gene, BAT1, may encode a protein that down-regulates cytokine production
###end article-title 92
###begin article-title 93
Alleles of the proximal promoter of BAT1, a putative anti-inflammatory gene adjacent to the TNF cluster, reduce transcription on a disease-associated MHC haplotype
###end article-title 93
###begin article-title 94
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human major histocompatibility complex contains a minimum of 19 genes between the complement cluster and HLA-B
###end article-title 94
###begin article-title 95
###xml 17 41 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families
###end article-title 95
###begin article-title 96
Mutational analysis of a DEAD box RNA helicase: the mammalian translation initiation factor eIF-4A
###end article-title 96
###begin article-title 97
High-Density SNP genotyping defines 17 distinct haplotypes of the TNF block in the Caucasian population: implications for haplotype tagging
###end article-title 97
###begin article-title 98
Neurological signs, aging, and the neurodegenerative syndromes
###end article-title 98
###begin article-title 99
###xml 52 58 <span type="species:ncbi:9606">people</span>
Neurodegenerative and other chronic disorders among people aged 75 years and over in the community
###end article-title 99
###begin article-title 100
###xml 4 10 <span type="species:ncbi:9557">baboon</span>
The baboon gene for apolipoprotein A-I: characterization of a cDNA clone and identification of DNA polymorphisms for genetic studies of cholesterol metabolism
###end article-title 100
###begin article-title 101
Novel polymorphism in the promoter region of the tumor necrosis factor alpha gene: No association with narcolepsy
###end article-title 101
###begin article-title 102
Haplotypic single nucleotide polymorphisms in the central MHC gene IKBL, a potential regulator of NF-kappaB function
###end article-title 102
###begin article-title 103
A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm
###end article-title 103
###begin article-title 104
Biased tests of association: comparisons of allele frequencies when departing from Hardy-Weinberg proportions
###end article-title 104
###begin article-title 105
Inflammation and Alzheimer's disease
###end article-title 105
###begin article-title 106
Peripheral inflammatory response in Alzheimer's disease and multiinfarct dementia
###end article-title 106
###begin article-title 107
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Peripheral cytokine release in Alzheimer patients: correlation with disease severity
###end article-title 107
###begin article-title 108
###xml 90 98 <span type="species:ncbi:9606">patients</span>
The role of -850 tumor necrosis factor-alpha and apolipoprotein E genetic polymorphism in patients with Down's syndrome-related dementia
###end article-title 108
###begin article-title 109
The DECD box putative ATPase Sub2p is an early mRNA export factor
###end article-title 109
###begin article-title 110
Splicing factor Sub2p is required for nuclear mRNA export through its interaction with Yra1p
###end article-title 110
###begin article-title 111
###xml 69 79 69 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 69 79 <span type="species:ncbi:7227">Drosophila</span>
The DExH/D protein HEL/UAP56 is essential for mRNA nuclear export in Drosophila
###end article-title 111
###begin article-title 112
Pre-mRNA splicing and mRNA export linked by direct interactions between UAP56 and Aly
###end article-title 112
###begin article-title 113
Polymorphisms at positions -22 and -348 in the promoter of the BAT1 gene affect transcription and the binding of nuclear factors
###end article-title 113
###begin article-title 114
Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors
###end article-title 114
###begin article-title 115
###xml 24 29 <span type="species:ncbi:9606">human</span>
Characterisation of the human central MHC gene, BAT1: genomic structure and expression
###end article-title 115

